Activation of the NURR1/RXRα heterodimer by NURR1 agonists can stand as a monotherapy for PD to increase striatal DA levels and upregulate NURR1 target genes in PD-like brain conditions [22]. The gene discussed is NR4A2; the disease is Parkinson disease.